Prometheus: The First Adjustable Dose Gene Therapy Platform Technology
Time: 1:45 pm
day: Conference Day Two
Details:
- An engineered gene therapy by design: ultra-low-cost, non-antigenic, specific, localized, and exceptionally well tolerated
- Overcoming the challenges of gene therapy’s fixed dose nature via a novel dose adjustment mechanism
- Enabling the replacement of subcutaneous protein treatments, with zero-order kinetics delivery
Speakers:
